Alternaria allergy immunotherapy - Probelte Pharma
Alternative Names: Beltavac Polimerizado; BeltavacPolimerizado; SCIT - Probelte Pharma; Subcutaneous allergen-specific immunotherapy - Probelte PharmaLatest Information Update: 10 Oct 2021
At a glance
- Originator Probelte Pharma
- Class Allergens; Antiallergics; Fungal allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Allergic asthma; Allergic rhinoconjunctivitis
Most Recent Events
- 15 Sep 2021 Probelte Pharma initiates a phase II trial in Allergic rhinoconjunctivitis (In adolescents, In adults) in Spain (SC) (EudraCT2018-003427-11)
- 07 Jun 2018 Launched for Allergic asthma (In children, In adolescents, In adults, In the elderly) in Spain (SC) before June 2018 (NCT03604718) (Probelte Pharma website)
- 07 Jun 2018 Launched for Allergic rhinoconjunctivitis (In children, In adolescents, In adults, In the elderly) in Spain (SC) before June 2018 (NCT03604718) (Probelte Pharma website)